Labcorp has been keeping pace with trends in the bio-tech and healthcare markets. The company's revenues have consistently beaten expectations, even though earnings per share (EPS) have missed in certain quarters, including Q4 2024 and the full year 2023. The company has shown stability, maintaining quarterly cash dividends for 2025, been upgraded to 'Outperform' and received positive cost synergies outlooks. It is also notable that a few firms have adjusted their holdings in Labcorp, with several increasing their stake, and a few selling shares. One of the major developments for Labcorp was acquiring select assets of
Invitae and
BioReference Health's Diagnostics Business. Simultaneously, the company was embarking on large senior notes issuance estimated in billions.
Laboratory Corporation of America has also stepped into the rapidly evolving landscape of molecular testing with the launch of an H5 Bird Flu Test and secured FDA approval for a Hemophilia companion diagnostic. The company's continued expansion into new market areas is seen with the strategic partnership with
Tufts Medicine, the sale of its Outreach Lab business, and its plan to spin off its clinical development unit. However, the market responded with a drop in Labcorp's share price following the announcement.
Laboratory Corporation of America Holdings LH News Analytics from Tue, 25 Apr 2017 07:00:00 GMT to Sat, 08 Feb 2025 09:24:10 GMT -
Rating 6
- Innovation 5
- Information 7
- Rumor 2
